Percutaneous Sclerotherapy for Management of Large Hepatic Haemangioma: First Series from Bangladesh
DOI:
https://doi.org/10.14738/bjhr.1202.18613Abstract
Introduction: Hepatic haemangiomas are non-malignant hepatic vascular malformations, which are usually asymptomatic, but may be a potential cause of life-threatening complications requiring urgent surgical intervention. Methods: Of the wide range of treatment modalities currently available for hepatic haemangiomas, we opted for percutaneous sclerotherapy with a combination of bleomycin and lipiodol. Results: We included 20 patients with hepatic haemangiomas in this single arm, single centre study, all underwent percutaneous sclerotherapy with combination bleomycin and lipiodol. Patients tolerated the procedure well, with no significant adverse event reported. Reduction of size of hepatic haemangiomas was achieved in 70% of patients at 6-month follow-up. Conclusion: The study shows that percutaneous sclerotherapy with bleomycin and lipiodol is safe and effective for management of hepatic haemangiomas.
References
Merrow AC, Gupta A, Patel MN, Adams DM. 2014 revised classification of vascular lesions from the International Society for the Study of Vascular Anomalies: radiologic-pathologic update. RadioGraphics 2016;36(5):1494–1516.
Lowe LH, Marchant TC, Rivard DC, Scherbel AJ. Vascular malformations: classification and terminology the radiologist needs to know. Semin Roentgenol 2012;47(2):106–117.
van Vugt LJ, van der Vleuten CJM, Flucke U, Blokx WAM. The utility of GLUT1 as a diagnostic marker in cutaneous vascular anomalies: a review of literature and recommendations for daily practice. Pathol Res Pract 2017;213(6):591–597.
Danza FM, De Franco A, Marino V, Fasanelli L, Coscarella G, Rossi P, Bock E. Percutaneous sclerosis of giant cavernous hepatic hemangioma: preliminary report of two cases. In International Congress Series. Vol. 1230. Elsevier; 2001. p. 1083–7.
Ayoobi Yazdi N, Mehrabinejad M-M, Dashti H, Pourghorban R, Nassiri Toosi M, Rokni Yazdi H. Percutaneous sclerotherapy with bleomycin and ethiodized oil: a promising treatment in symptomatic giant liver hemangioma. Radiology. 2021;301(2):464–71.
Merrow AC, Gupta A, Patel MN, Adams DM. 2014 revised classification of vascular lesions from the international society for the study of vascular anomalies: radiologic-pathologic update. Radiographics. 2016;36(5):1494–516.
Dong W, Qiu B, Xu H, He L. Invasive management of symptomatic hepatic hemangioma. Eur J Gastroenterol Hepatol. 2019;31(9):1079–84.
Ayoobi Yazdi N, Dashti H, Batavani N, Borhani A, Shakiba M, Rokni Yazdi H. Percutaneous Sclerotherapy for Giant Symptomatic Liver Hemangiomas: A Pilot Study. J Vasc Interv Radiol. 2018 Feb;29(2):233-236. doi: 10.1016/j.jvir.2017.10.009. PMID: 29414196.
National news on Somoy TV, Bangladesh on 22/12/2024; https://www.somoynews.tv/
Burrows PE, Mason KP. Percutaneous treatment of low flow vascular malformations. J Vasc Interv Radiol 2004;15(5):431–445.
Muir T, Kirsten M, Fourie P, Dippenaar N, Ionescu GO. Intralesional bleomycin injection (IBI) treatment for haemangiomas and congenital vascular malformations. Pediatr Surg Int 2004;19(12):766–773.
Spence J, Krings T, TerBrugge KG, Agid R. Percutaneous treatment of facial venous malformations: a matched comparison of alcohol and bleomycin sclerotherapy. Head Neck 2011;33(1):125–130.
Torkian P, Li J, Kaufman JA, Jahangiri Y. Effectiveness of transarterial embolization in treatment of symptomatic hepatic hemangiomas: systematic review and meta-analysis. Cardiovasc Intervent Radiol. 2021;44(1):80–91.
Han Q, Lin L, Zhao B, Wang N, Liu X. Inhibition of mTOR ameliorates bleomycin-induced pulmonary fibrosis by regulating epithelial-mesenchymal transition. Biochem Biophys Res Commun 2018;500(4):839–845.
Horbach SER, Rigter IM, Smitt JHS, Reekers JA, Spuls PI, van der Horst CMAM. Intralesional bleomycin injections for vascular malformations: a systematic review and meta-analysis. Plast Reconstr Surg Ayoobi Yazdi N2016;137(1):244–256.
Furumaya A, van Rosmalen BV, Takkenberg RB, et al. Transarterial (chemo-) embolization and lipiodolization for hepatic haemangioma. Cardiovasc Intervent Radiol 2019;42(6):800–811.
Akhlaghpoor S, Torkian P, Golzarian J. Transarterial bleomycin–Lipiodol embolization (B/LE) for symptomatic giant hepatic hemangioma. Cardiovasc Intervent Radiol 2018;41(11):1674–1682.
Bozkaya H, Cinar C, Besir FH, Parıldar M, Oran I. Minimally invasive treatment of giant haemangiomas of the liver: embolisation with bleomycin. Cardiovasc Intervent Radiol 2014;37(1):101–107.
Kirnap M, Boyvat F, Boyacioglu S, Hilmioglu F, Moray G, Haberal M. The effect of bleomycin embolization on symptomatic improvement and hemangioma size among patients with giant liver hemangiomas. Open J Gastroenterol 2018;8(4):130–139 https://doi.org/10.4236/ojgas.2018.84014.
Özden İ, Poyanlı A, Önal Y, Demir AA, Hoş G, Acunaş B. Superselective transarterial chemoembolization as an alternative to surgery in symptomatic/enlarging liver hemangiomas. World J Surg 2017;41(11):2796–2803.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Ahmed Lutful Moben, Sheikh Mohammad Noor E Alam, Rokshana Begum, Md. Abdur Rahim, Omar Faruque Sadman, Md. Abdur Rahman, Nasif Shahriar, Nadia Binte Nasir, Nirupoma Das, Taslima Akter Lima, Tasnim Mahmud, Musarrat Mahtab, Sheikh Mohammad Fazle Akbar, Mamun Al Mahtab
This work is licensed under a Creative Commons Attribution 4.0 International License.
